Abstract
Nephrotoxicity is a major side effect of cisplatin, a widely used cancer therapy drug. Depending on its concentration, cisplatin induces necrosis or apoptosis of tubular cells in the kidneys, whereas the underlying injury mechanism is unclear. Our recent work has suggested a critical role for p53 in cisplatin-induced tubular cell apoptosis; nevertheless, the apoptotic events triggered by p53 remain elusive. The current study has examined Bcl-2 family proteins, critical regulators of apoptosis that may be subjected to p53 regulation. Following cisplatin treatment, the expression of Bcl-xL, an antiapoptotic molecule, was suppressed, while the expression of Bak, a proapoptotic molecule, increased slightly. Of interest, PUMA-α, a newly identified p53-responsive proapoptotic Bcl-2 family protein, was drastically induced by cisplatin. PUMA-α induction preceded or paralleled the development of apoptosis. Induced PUMA-α was localized in mitochondria and appeared to antagonize Bcl-xL via molecular interaction. PUMA-α induction during cisplatin treatment was attenuated by pifithrin-α, a pharmacological inhibitor of p53, which was accompanied by the amelioration of Bax activation, cytochrome c release and apoptosis. Moreover, PUMA-α induction was suppressed by dominant-negative p53. Importantly, cisplatin-induced apoptosis was ameliorated in PUMA-α knockout cells. In vivo, cisplatin induced PUMA-α in the kidneys, and the inductive response was abrogated in p53-deficient animals. Together, this study has demonstrated the first compelling evidence for the involvement of PUMA-α in p53-mediated renal cell apoptosis during cisplatin nephrotoxicity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adams JM, Cory S . (1998). Science 281: 1322–1326.
Akeshima R, Kigawa J, Takahashi M, Oishi T, Kanamori Y, Itamochi H et al. (2001). Br J Cancer 84: 1551–1555.
Arany I, Megyesi JK, Kaneto H, Price PM, Safirstein RL . (2004). Am J Physiol Renal Physiol 287: F543–F549.
Arany I, Safirstein RL . (2003). Semin Nephrol 23: 460–464.
Baliga R, Zhang Z, Baliga M, Ueda N, Shah SV . (1998). Kidney Int 53: 394–401.
Chang J, Hsu Y, Kuo P, Kuo Y, Chiang L, Lin C . (2005). Life Sci 76: 1883–1893.
Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T et al. (2001). Mol Cell 8: 705–711.
Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR . (2005). Science 309: 1732–1735.
Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M et al. (2004). Science 303: 1010–1014.
Cummings BS, Schnellmann RG . (2002). J Pharmacol Exp Ther 302: 8–17.
Danial NN, Korsmeyer SJ . (2004). Cell 116: 205–219.
Dong Z, Wang J . (2004). J Biol Chem 279: 9215–9221.
Dong Z, Wang JZ, Yu F, Venkatachalam MA . (2003). Am J Pathol 163: 663–671.
Fuertesa MA, Castillab J, Alonsoa C, Perez JM . (2003). Curr Med Chem 10: 257–266.
Gottlieb RA, Granville DJ . (2002). Methods 26: 341–347.
Green DR, Kroemer G . (2004). Science 305: 626–629.
Gudkov AV, Komarova EA . (2005). Biochem Biophys Res Commun 331: 726–736.
Hsu YT, Youle RJ . (1998). J Biol Chem 273: 10777–10783.
Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J et al. (2003). Cancer Cell 4: 321–328.
Jiang M, Yi X, Hsu S, Wang CY, Dong Z . (2004). Am J Physiol Renal Physiol 287: F1140–F1147.
Kaushal GP, Kaushal V, Hong X, Shah SV . (2001). Kidney Int 60: 1726–1736.
Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV et al. (1999). Science 285: 1733–1737.
Li S, Basnakian A, Bhatt R, Megyesi J, Gokden N, Shah SV et al. (2004). Am J Physiol Renal Physiol 287: F990–F998.
Liu H, Baliga R . (2003). Kidney Int 63: 1687–1696.
Martinou JC, Green DR . (2001). Nat Rev Mol Cell Biol 2: 63–67.
Megyesi J, Safirstein RL, Price PM . (1998). J Clin Invest 101: 777–782.
Miyashita T, Reed JC . (1995). Cell 80: 293–299.
Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ . (1998). Proc Natl Acad Sci USA 95: 5724–5729.
Nakano K, Vousden KH . (2001). Mol Cell 7: 683–694.
Niedner H, Christen R, Lin X, Kondo A, Howell SB . (2001). Mol Pharmacol 60: 1153–1160.
Nowak G . (2002). J Biol Chem 277: 43377–43388.
Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T et al. (2000). Science 288: 1053–1058.
Park MS, De Leon M, Devarajan P . (2002). J Am Soc Nephrol 13: 858–865.
Ramesh G, Reeves WB . (2002). J Clin Invest 110: 835–842.
Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS . (2002). Nat Cell Biol 4: 842–849.
Sheikh-Hamad D, Cacini W, Buckley AR, Isaac J, Truong LD, Tsao CC et al. (2004). Arch Toxicol 78: 147–155.
Shen ZN, Nishida K, Doi H, Oohashi T, Hirohata S, Ozaki T et al. (2005). Biochem Biophys Res Commun 328: 375–382.
Shiraishi F, Curtis LM, Truong L, Poss K, Visner GA, Madsen K et al. (2000). Am J Physiol Renal Physiol 278: F726–F736.
Siddik ZH . (2003). Oncogene 22: 7265–7279.
Tomasoni S, Benigni A . (2004). Curr Gene Ther 4: 115–122.
Tomita N, Azuma H, Kaneda Y, Ogihara T, Morishita R . (2004). Curr Drug Targets 5: 717–733.
Tsuruya K, Ninomiya T, Tokumoto M, Hirakawa M, Masutani K, Taniguchi M et al. (2003). Kidney Int 63: 72–82.
Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ et al. (2003). Science 302: 1036–1038.
Vousden KH, Lu X . (2002). Nat Rev Cancer 2: 594–604.
Wang J, Wei Q, Wang CY, Hill WD, Hess DC, Dong Z . (2004). J Biol Chem 279: 19948–19954.
Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ et al. (2001). Science 292: 727–730.
Wei Q, Wang MH, Dong Z . (2005). Am J Nephrol 25: 491–499.
Woost PG, Orosz DE, Jin W, Frisa PS, Jacobberger JW, Douglas JG et al. (1996). Kidney Int 50: 125–134.
Yi X, Yin XM, Dong Z . (2003). J Biol Chem 278: 16992–16999.
Yu F, Megyesi J, Safirstein RL, Price PM . (2005). Am J Physiol Renal Physiol 289: F514–F520.
Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L . (2003). Proc Natl Acad Sci USA 100: 1931–1936.
Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B . (2001). Mol Cell 7: 673–682.
Acknowledgements
We thank Drs Mivechi and Moskophidis at the Medical College of Georgia for providing the breeding pairs of p53-deficient mice. We also thank Dr Xiao-Ming Yin at the University of Pittsburgh for the polyclonal antibody to Bid. This study was supported in part by grants from National Institutes of Health and Department of Veterans Affairs.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jiang, M., Wei, Q., Wang, J. et al. Regulation of PUMA-α by p53 in cisplatin-induced renal cell apoptosis. Oncogene 25, 4056–4066 (2006). https://doi.org/10.1038/sj.onc.1209440
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209440
Keywords
This article is cited by
-
Cytosine–phosphate–guanine oligodeoxynucleotides alleviate radiation-induced kidney injury in cervical cancer by inhibiting DNA damage and oxidative stress through blockade of PARP1/XRCC1 axis
Journal of Translational Medicine (2023)
-
Pathological consequences of DNA damage in the kidney
Nature Reviews Nephrology (2023)
-
Leonurine attenuates cisplatin nephrotoxicity by suppressing the NLRP3 inflammasome, mitochondrial dysfunction, and endoplasmic reticulum stress
International Urology and Nephrology (2022)
-
Emerging role of tumor suppressor p53 in acute and chronic kidney diseases
Cellular and Molecular Life Sciences (2022)
-
Platinum drugs and taxanes: can we overcome resistance?
Cell Death Discovery (2021)